Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Ovarian Neoplasms × abagovomab × Clear all

Phase

Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 6 liposomal doxorubicin 4 Carboplatin 4 Topotecan 3 Gemcitabine 2 Drug Therapy 2 Doxorubicin 2 Bevacizumab 2 trametinib 1 saracatinib 1 pertuzumab 1 pegfilgrastim 1 olaparib 1 masitinib 1 dabrafenib 1 cobimetinib 1 cediranib 1 atezolizumab 1 aflibercept 1 abagovomab 1 Vemurafenib 1 Trastuzumab 1 Taxes 1 Poly(ADP-ribose) Polymerase Inhibitors 1 Neoadjuvant Therapy 1 Magnetic Resonance Spectroscopy 1 Immunoglobulin G 1 Ifosfamide 1 Disulfides 1 Diathermy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00418574 2011-11-24

MIMOSA

Menarini Group

Phase 2/3 Terminated

888 enrolled 17 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡